BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23028042)

  • 21. Protein phosphatase 1 inhibits p53 signaling by dephosphorylating and stabilizing Mdmx.
    Lu Z; Wan G; Guo H; Zhang X; Lu X
    Cell Signal; 2013 Apr; 25(4):796-804. PubMed ID: 23277204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.
    Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS
    Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural and molecular basis of interaction of HCV non-structural protein 5A with human casein kinase 1α and PKR.
    Sudha G; Yamunadevi S; Tyagi N; Das S; Srinivasan N
    BMC Struct Biol; 2012 Nov; 12():28. PubMed ID: 23148689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress.
    Biderman L; Poyurovsky MV; Assia Y; Manley JL; Prives C
    Mol Cell Biol; 2012 Apr; 32(7):1214-25. PubMed ID: 22290440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation.
    Waning DL; Lehman JA; Batuello CN; Mayo LD
    J Biol Chem; 2011 Jan; 286(1):216-22. PubMed ID: 21081495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
    Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
    J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.
    Meulmeester E; Pereg Y; Shiloh Y; Jochemsen AG
    Cell Cycle; 2005 Sep; 4(9):1166-70. PubMed ID: 16082221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDM2 promotes ubiquitination and degradation of MDMX.
    Pan Y; Chen J
    Mol Cell Biol; 2003 Aug; 23(15):5113-21. PubMed ID: 12860999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
    ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
    Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
    Shan B; Li DW; Brüschweiler-Li L; Brüschweiler R
    J Biol Chem; 2012 Aug; 287(36):30376-84. PubMed ID: 22807444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.
    Hu B; Gilkes DM; Farooqi B; Sebti SM; Chen J
    J Biol Chem; 2006 Nov; 281(44):33030-5. PubMed ID: 16905541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abnormal MDMX degradation in tumor cells due to ARF deficiency.
    Li X; Gilkes D; Li B; Cheng Q; Pernazza D; Lawrence H; Lawrence N; Chen J
    Oncogene; 2012 Aug; 31(32):3721-32. PubMed ID: 22120712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functions of MDMX in the modulation of the p53-response.
    Lenos K; Jochemsen AG
    J Biomed Biotechnol; 2011; 2011():876173. PubMed ID: 21541195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring Ligand-Induced Protein Ordering in Drug Discovery.
    Grace CR; Ban D; Min J; Mayasundari A; Min L; Finch KE; Griffiths L; Bharatham N; Bashford D; Kiplin Guy R; Dyer MA; Kriwacki RW
    J Mol Biol; 2016 Mar; 428(6):1290-1303. PubMed ID: 26812210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MDMX: a novel p53-binding protein with some functional properties of MDM2.
    Shvarts A; Steegenga WT; Riteco N; van Laar T; Dekker P; Bazuine M; van Ham RC; van der Houven van Oordt W; Hateboer G; van der Eb AJ; Jochemsen AG
    EMBO J; 1996 Oct; 15(19):5349-57. PubMed ID: 8895579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers.
    Dolezelova P; Cetkovska K; Vousden KH; Uldrijan S
    Cell Cycle; 2012 Mar; 11(5):953-62. PubMed ID: 22333590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MDMX inhibits the p300/CBP-mediated acetylation of p53.
    Sabbatini P; McCormick F
    DNA Cell Biol; 2002 Jul; 21(7):519-25. PubMed ID: 12162806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
    Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
    Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.